/CMND
CMND Stock - Clearmind Medicine Inc.
Healthcare|BiotechnologyNASDAQ
$2.74+4.98%
+$0.13 (+4.98%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CMND
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.71 – $2.77
TARGET (TP)$3.15
STOP LOSS$2.52
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.19
52W High$87.20
52W Low$2.36
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-26,703 | $-56,342 | $-113,379 | $-2,572 | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-7,998,946 | $-8,741,350 | $-8,532,579 | $-3,676,217 | $-233,220 |
| Net Income | $-5,254,678 | $-11,955,031 | $-9,410,806 | $-3,719,745 | $-412,909 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-67.60 | $-1703.20 | $-6744.40 | $-4812.00 | $-382.40 |
Company Overview
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
CMNDBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.25
Q3 2025
EPS Surprise History
Q1 24
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q1 25
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Jan 28, 2026 | — | — | — | — |
Q3 2025 | Sep 11, 2025 | — | $-0.25 | — | — |
Q2 2025 | Jun 12, 2025 | — | $-0.16 | — | — |
Q1 2025 | Mar 13, 2025 | — | $-0.24 | — | — |
Q1 2025 | Jan 22, 2025 | — | $-0.11 | — | — |
Q3 2024 | Sep 16, 2024 | — | $-0.59 | — | — |
Q2 2024 | Jun 13, 2024 | — | $-0.28 | — | — |
Q1 2024 | Mar 18, 2024 | — | $-0.90 | — | — |
Q1 2024 | Jan 29, 2024 | — | $-33.24 | — | — |
Q3 2023 | Sep 13, 2023 | — | $-0.08 | — | — |
Q2 2023 | Jun 14, 2023 | — | $-48.90 | — | — |
Q1 2023 | Mar 17, 2023 | — | $-96.20 | — | — |
Q1 2023 | Feb 3, 2023 | — | $-238.58 | — | — |
Q3 2022 | Jul 31, 2022 | — | $-199.07 | — | — |
Q2 2022 | Apr 30, 2022 | — | $-317.31 | — | — |
Q1 2022 | Jan 31, 2022 | — | $-200.43 | — | — |
Q4 2021 | Oct 31, 2021 | — | $-237.36 | — | — |
Q3 2021 | Jul 31, 2021 | — | $-121.72 | — | — |
Q2 2021 | Apr 30, 2021 | — | $-35.25 | — | — |
Q1 2021 | Jan 31, 2021 | — | $-18.47 | — | — |
Latest News
Clearmind Medicine Completes Enrollment For Second Cohort Of Phase I/IIa AUD Trial Of CMND-100
📈 PositiveBenzinga•Dec 16, 2025, 01:46 PM
Clearmind Medicine Regains Nasdaq Compliance
📈 PositiveBenzinga•Dec 12, 2025, 11:33 AM
Clearmind Medicine shares are trading lower after the company announced a 1-for-40 reverse share split.
📉 NegativeBenzinga•Dec 11, 2025, 02:02 PM
Clearmind Medicine shares are trading lower after the company announced a 1-for-40 reverse share split.
📉 NegativeBenzinga•Dec 10, 2025, 09:30 PM
Clearmind Medicine Announces 1-for-40 Reverse Share Split, Effective Dec. 15
📉 NegativeBenzinga•Dec 10, 2025, 09:20 PM
Clearmind Medicine to enact 1-for-40 reverse share split; shares down
📉 NegativeSeeking Alpha•Dec 10, 2025, 09:20 PM
Clearmind Medicine Receives Nasdaq Notice For Low Share Price, Has Until June 2026 To Regain Compliance
➖ NeutralBenzinga•Dec 5, 2025, 10:06 PM
Clearmind Medicine Announces First Participant Enrolled And Dosed With CMND-100, Proprietary MEAI-Based Oral Drug Candidate, At Hadassah-University Medical Center In Jerusalem, Israel
📈 PositiveBenzinga•Dec 2, 2025, 01:00 PM
Clearmind Medicine Advances CMND-100 Trial With Early Results, DSMB Approval, and New Global Site Enrollment in Push to Treat Alcohol Use Disorder
📈 PositiveBenzinga•Dec 1, 2025, 02:04 PM
Clearmind Medicine shares are trading lower. The company announced that Tel Aviv Sourasky Medical Center enrolled first patient for FDA-approved multinational Phase I/IIa clinical trial of CMND-100 in Alcohol Use Disorder.
➖ NeutralBenzinga•Nov 25, 2025, 05:57 PM
Clearmind Medicine Enrolls First Patient At Tel Aviv Sourasky Medical Center In FDA-Approved Multinational Phase I/IIa Trial Of CMND-100 For Alcohol Use Disorder
📈 PositiveBenzinga•Nov 25, 2025, 12:18 PM
Clearmind's Independent DSMB Completes Scheduled Interim Review Of Ongoing FDA-Approved Phase I/IIa Clinical Trial For CMND-100, Proprietary, Non-Hallucinogenic Neuroplastogen, In AUD Treatment
➖ NeutralBenzinga•Nov 24, 2025, 01:54 PM
SciSparc Says NeuroThera Advances Collaboration With Clearmind Medicine By Filing Israeli Patent Application For Combination Therapy Of 5-Methoxy-2-Aminoindane And N-Acylethanolamines, Targeting Depression
📈 PositiveBenzinga•Nov 20, 2025, 11:47 AM•Also:
Clearmind Medicine Data From First Group Of Phase I/IIa Clinical Study Of CMND-100 Shows Favorable Safety Profile, No Serious Adverse Events For Treatment Of Alcohol Use Disorder
📈 PositiveBenzinga•Nov 18, 2025, 01:59 PM
Clearmind Medicine Files Israeli Patent Application For Combination Therapy Of 5-Methoxy-2-Aminoindane And N-Acylethanolamines, Addressing Depression
📈 PositiveBenzinga•Nov 17, 2025, 12:57 PM
Clearmind Receives Final Approval From Hadassah Medical Center, Jerusalem, For Ongoing Phase 1/2a Clinical Trial Evaluating CMND-100, Proprietary MEAI-Based Oral Drug Candidate, For AUD Treatment
📈 PositiveBenzinga•Nov 13, 2025, 01:56 PM
Clearmind Medicine Announces CNIPA Publication Of Patent For MEAI Compound In Depression Treatment
📈 PositiveBenzinga•Nov 12, 2025, 11:28 AM
Clearmind Medicine Completes First Patient Cohort In Phase I/IIa Trial Of MEAI-Based CMND-100 For Alcohol Use Disorder
📈 PositiveBenzinga•Nov 10, 2025, 01:11 PM
Clearmind Medicine shares are trading lower after the company announced it received a Nasdaq delisting notification
📉 NegativeBenzinga•Nov 7, 2025, 04:56 PM
Clearmind Medicine shares are trading lower after the company announced it received a Nasdaq delisting notification
📉 NegativeBenzinga•Nov 6, 2025, 10:07 PM
Frequently Asked Questions about CMND
What is CMND's current stock price?
Clearmind Medicine Inc. (CMND) is currently trading at $2.74 per share. The stock has moved +4.98% today.
What is the analyst price target for CMND?
No analyst price targets are currently available for this stock.
What sector is Clearmind Medicine Inc. in?
Clearmind Medicine Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CMND's market cap?
Clearmind Medicine Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does CMND pay dividends?
No, Clearmind Medicine Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCANF
Can-Fite BioPharma Ltd.
$0.25
Mkt Cap: $0.0B
CLDI
Calidi Biotherapeutics, Inc.
$1.36
Mkt Cap: $0.0B
CNSP
CNS Pharmaceuticals, Inc.
$6.51
Mkt Cap: $0.0B
GRI
GRI Bio, Inc.
$0.34
Mkt Cap: $0.0B
JAGX
Jaguar Health, Inc.
$1.17
Mkt Cap: $0.0B
KZIA
Kazia Therapeutics Limited
$10.87
Mkt Cap: $0.0B
SILO
Silo Pharma, Inc.
$0.38
Mkt Cap: $0.0B
SNGX
Soligenix, Inc.
$1.38
Mkt Cap: $0.0B
TTNP
Titan Pharmaceuticals, Inc.
$2.34
Mkt Cap: $0.0B
XBIO
Xenetic Biosciences, Inc.
$2.15
Mkt Cap: $0.0B
Explore stocks similar to CMND for comparison